{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:31:32Z","timestamp":1782916292020,"version":"3.54.5"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.eclinm.2021.101148","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T09:42:41Z","timestamp":1634636561000},"page":"101148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Outcomes of real-world integrated HCV microelimination for people who inject drugs: an expansion of the punjab model"],"prefix":"10.1016","volume":"41","author":[{"given":"Radha K.","family":"Dhiman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagandeep S.","family":"Grover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2961-4148","authenticated-orcid":false,"given":"Madhumita","family":"Premkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Taneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Duseja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2021.101148_bib0001","year":"2016","journal-title":"Guidelines for the screening, care, and treatment of persons with chronic hepatitis C infection Updated version"},{"issue":"17","key":"10.1016\/j.eclinm.2021.101148_bib0002","first-page":"453","article-title":"Centers for Disease Control and Prevention (CDC). Increases in hepatitis C virus infection related to injection drug use among persons aged \u226430 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012","volume":"64","author":"Zibbell","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.eclinm.2021.101148_bib0003","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ajp.2012.08.008","article-title":"Seroprevalence of anti-hepatitis C virus (anti-HCV) antibody and HCV-related risk in injecting drug users in northern India: Comparison with non-injecting drug users","volume":"6","author":"Basu","year":"2013","journal-title":"Asian Journal of Psychiatry"},{"issue":"6","key":"10.1016\/j.eclinm.2021.101148_bib0004","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jhep.2019.07.006","article-title":"MMPHCRF Investigators. Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting","volume":"71","author":"Dhiman","year":"2019","journal-title":"J Hepatol."},{"issue":"1","key":"10.1016\/j.eclinm.2021.101148_bib0005","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1473-3099(14)71045-X","article-title":"Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study","volume":"15","author":"Solomon","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.eclinm.2021.101148_bib0006","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1186\/s12889-015-2003-z","article-title":"HIV, Hepatitis B and C among people who inject drugs: high prevalence of HIV and Hepatitis C RNA positive infections observed in Delhi, India","volume":"15","author":"Ray Saraswati","year":"2015","journal-title":"BMC Public Health"},{"key":"10.1016\/j.eclinm.2021.101148_bib0007","first-page":"37","article-title":"Prevalence of HCV & HBV infection amongst HIV seropositive intravenous drug users & their non-injecting wives in Manipur","volume":"111","author":"Saha","year":"2000","journal-title":"India. Indian J Med Res."},{"issue":"2","key":"10.1016\/j.eclinm.2021.101148_bib0008","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/jgh.14466","article-title":"Burden of hepatitis C virus infection in India: A systematic review and meta-analysis","volume":"34","author":"Goel","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2021.101148_bib0009","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1747-597X-7-9","article-title":"Size estimation of injecting drug users (IDU) using multiplier method in five districts of India","volume":"7","author":"Medhi","year":"2012","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"3","key":"10.1016\/j.eclinm.2021.101148_bib0010","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11938-019-00240-7","article-title":"Hepatitis C elimination: a Public Health Perspective","volume":"17","author":"Dhiman","year":"2019","journal-title":"Curr Treat Options Gastroenterol"},{"key":"10.1016\/j.eclinm.2021.101148_bib0011","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3109\/10826084.2016.1161054","article-title":"Clinicians\u2019 views of hepatitis C virus treatment candidacy with direct-acting antiviral regimens for people who inject drugs","volume":"51","author":"Asher","year":"2016","journal-title":"Subst Use Misuse"},{"key":"10.1016\/j.eclinm.2021.101148_bib0012","doi-asserted-by":"crossref","unstructured":"Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B. . Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. The Lancet Gastroenterology & Hepatology, 3(3), 153\u2013161.","DOI":"10.1016\/S2468-1253(17)30404-1"},{"key":"10.1016\/j.eclinm.2021.101148_bib0013","first-page":"pii","article-title":"Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study","author":"Akiyama","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.eclinm.2021.101148_bib0014","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1177\/0956462413515659","article-title":"Alarming epidemics of human immunodeficiency virus and hepatitis C virus among injection drug users in the northwestern bordering state of Punjab, India: prevalence and correlates","volume":"25","author":"Panda","year":"2013","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.eclinm.2021.101148_bib0015","article-title":"Adherence to Direct-Acting Antiviral Therapy in People Actively Using Drugs and Alcohol: The INCLUD Study","author":"Brooks","year":"2021","journal-title":"InOpen Forum Infectious Diseases"},{"key":"10.1016\/j.eclinm.2021.101148_bib0016","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/MPG.0000000000002139","article-title":"Direct-acting antiviral therapy is safe and effective in pediatric chronic hepatitis C: The public health perspective","volume":"68","author":"Dhiman","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.eclinm.2021.101148_bib0017","year":"2021","journal-title":"National Viral Hepatitis Control Program- Operational guidelines, 2018 by Ministry of Health and Family Welfare, Government of India"},{"issue":"8","key":"10.1016\/j.eclinm.2021.101148_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221769","article-title":"Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India","volume":"14","author":"Chugh","year":"2019","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.eclinm.2021.101148_bib0019","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-042280","article-title":"Cost-effectiveness and budget impact analysis of facility-based screening and treatment of hepatitis C in Punjab state of India","volume":"11","author":"Chugh","year":"2021","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.eclinm.2021.101148_bib0020","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/j.ijid.2009.03.002","article-title":"HIV, hepatitis C virus, and hepatitis B virus co-infections among injecting drug users in Tehran, Iran","volume":"14","author":"Rahimi-Movaghar","year":"2010","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.eclinm.2021.101148_bib0021","doi-asserted-by":"crossref","first-page":"h2445","DOI":"10.1136\/bmj.h2445","article-title":"Deviation from intention to treat analysis in randomized trials and treatment effect estimates: metaepidemiological study","volume":"27","author":"Abraha","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2021.101148_bib0022","doi-asserted-by":"crossref","unstructured":"Oru E, Trickey A, Shirali R, Kanters S, Easterbrook P. Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis. The Lancet Global Health. 2021;9(4):e431-e445. doi: 10.1016\/S2214-109X(20)30505-2.","DOI":"10.1016\/S2214-109X(20)30505-2"},{"issue":"8","key":"10.1016\/j.eclinm.2021.101148_bib0023","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/add.13821","article-title":"Epidemiology of HIV and hepatitis C infection among women who inject drugs in Northeast India: a respondent-driven sampling study","volume":"112","author":"McFall","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.eclinm.2021.101148_bib0024","first-page":"S176","article-title":"HIV, HCV, and Health-Related Harms Among Women Who Inject Drugs: Implications for Prevention and Treatment","volume":"69","author":"Iversen","year":"2015","journal-title":"JAIDS"},{"issue":"8\/9","key":"10.1016\/j.eclinm.2021.101148_bib0025","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1080\/10826080801918189","article-title":"Women and Substance Use in India and Bangladesh","volume":"43","author":"Kumar","year":"2008","journal-title":"Substance Use & Misuse"},{"key":"10.1016\/j.eclinm.2021.101148_bib0026","unstructured":"Ambekar A, Tripathi BM. Size Estimation of Injection Drug Use in Punjab and Haryana. report submitted to SPYM under the Peer led intervention \u2013 supported by DFID. Resource Centre, New Delhi. UNAIDS."},{"issue":"12","key":"10.1016\/j.eclinm.2021.101148_bib0027","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"The Lancet Global Health"},{"key":"10.1016\/j.eclinm.2021.101148_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2019.04.030","article-title":"Prescription opiate analgesics, heroin, HIV and HCV among persons who inject drugs in New York City, 2016-2018","volume":"204","author":"Des Jarlais","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.eclinm.2021.101148_bib0029","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/hep.26387","article-title":"The incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis","volume":"58","author":"Larney","year":"2013","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.eclinm.2021.101148_bib0030","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1093\/cid\/ciz985","article-title":"Moving Towards Hepatitis C Microelimination Among People Living With Human Immunodeficiency Virus in Australia: The CEASE Study","volume":"71","author":"Martinello","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.eclinm.2021.101148_bib0031","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1360-0443.2009.02759.x","article-title":"Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis","volume":"105","author":"Vickerman","year":"2010","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.eclinm.2021.101148_bib0032","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/cld.978","article-title":"Hepatitis C Virus Elimination by 2030: Conquering Mount Improbable","volume":"16","author":"Dhiman","year":"2021","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10.1016\/j.eclinm.2021.101148_bib0033","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.drugpo.2019.07.002","article-title":"An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study","volume":"72","author":"Alavi","year":"2019","journal-title":"Int J Drug Pol"},{"issue":"1","key":"10.1016\/j.eclinm.2021.101148_bib0034","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1477-7517-9-40","article-title":"Understanding the association between injecting and sexual risk behaviors of injecting drug users in Manipur and Nagaland, India","volume":"9","author":"Suohu","year":"2012","journal-title":"Harm Reduction Journal"},{"issue":"1","key":"10.1016\/j.eclinm.2021.101148_bib0035","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/infdis\/jir196","article-title":"A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs","volume":"204","author":"Hagan","year":"2011","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.eclinm.2021.101148_bib0036","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1093\/cid\/ciz696","article-title":"Efficacy of direct-acting antivirals for chronic hepatitis C virus infection in people who inject drugs or receive opioid substitution therapy: a systematic review and meta-analysis","volume":"70","author":"Graf","year":"2020","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"10.1016\/j.eclinm.2021.101148_bib0037","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2019.02.018","article-title":"Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy","volume":"71","author":"Mac\u00edas","year":"2019","journal-title":"Journal of hepatology"},{"issue":"3","key":"10.1016\/j.eclinm.2021.101148_bib0038","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1055\/s-0038-1666841","article-title":"The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations","volume":"38","author":"Lazarus","year":"2018","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.eclinm.2021.101148_bib0039","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.drugpo.2017.05.056","article-title":"Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: findings from the Queensland Injectors health network","volume":"47","author":"Morris","year":"2017","journal-title":"Int J Drug Policy"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537021004284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537021004284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T19:07:54Z","timestamp":1762888074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537021004284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":39,"alternative-id":["S2589537021004284"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2021.101148","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of real-world integrated HCV microelimination for people who inject drugs: an expansion of the punjab model","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2021.101148","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101148"}}